Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota |
PMID[11420884] |
|||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC284651 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.8684 | High Similarity | NPC149843 |
0.8684 | High Similarity | NPC155087 |
0.7632 | Intermediate Similarity | NPC283698 |
0.7632 | Intermediate Similarity | NPC73765 |
0.7544 | Intermediate Similarity | NPC17892 |
0.7544 | Intermediate Similarity | NPC36985 |
0.7438 | Intermediate Similarity | NPC329277 |
0.7368 | Intermediate Similarity | NPC322594 |
0.7368 | Intermediate Similarity | NPC320249 |
0.7353 | Intermediate Similarity | NPC318142 |
0.7281 | Intermediate Similarity | NPC324390 |
0.7197 | Intermediate Similarity | NPC325750 |
0.7034 | Intermediate Similarity | NPC317639 |
0.693 | Remote Similarity | NPC43246 |
0.693 | Remote Similarity | NPC89051 |
0.6807 | Remote Similarity | NPC324516 |
0.6807 | Remote Similarity | NPC318166 |
0.6797 | Remote Similarity | NPC316244 |
0.6667 | Remote Similarity | NPC106780 |
0.6639 | Remote Similarity | NPC327344 |
0.6504 | Remote Similarity | NPC328779 |
0.6475 | Remote Similarity | NPC315058 |
0.6471 | Remote Similarity | NPC171116 |
0.6471 | Remote Similarity | NPC315063 |
0.6423 | Remote Similarity | NPC90240 |
0.6423 | Remote Similarity | NPC120887 |
0.64 | Remote Similarity | NPC328914 |
0.6341 | Remote Similarity | NPC6166 |
0.6341 | Remote Similarity | NPC226769 |
0.6341 | Remote Similarity | NPC280946 |
0.6338 | Remote Similarity | NPC313962 |
0.6303 | Remote Similarity | NPC210456 |
0.6303 | Remote Similarity | NPC163352 |
0.626 | Remote Similarity | NPC329384 |
0.6134 | Remote Similarity | NPC325723 |
0.605 | Remote Similarity | NPC112842 |
0.605 | Remote Similarity | NPC71339 |
0.5862 | Remote Similarity | NPC329077 |
0.5827 | Remote Similarity | NPC313813 |
0.5772 | Remote Similarity | NPC190334 |
0.5772 | Remote Similarity | NPC62927 |
0.5682 | Remote Similarity | NPC188453 |
0.5682 | Remote Similarity | NPC42320 |
0.568 | Remote Similarity | NPC292345 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC284651 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.7632 | Intermediate Similarity | NPD9639 | Clinical (unspecified phase) |
0.7438 | Intermediate Similarity | NPD3129 | Phase 3 |
0.7355 | Intermediate Similarity | NPD3128 | Phase 3 |
0.7009 | Intermediate Similarity | NPD1686 | Approved |
0.6947 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.693 | Remote Similarity | NPD9580 | Clinical (unspecified phase) |
0.693 | Remote Similarity | NPD9581 | Clinical (unspecified phase) |
0.6923 | Remote Similarity | NPD3139 | Phase 3 |
0.6846 | Remote Similarity | NPD3138 | Phase 3 |
0.6724 | Remote Similarity | NPD241 | Discontinued |
0.6721 | Remote Similarity | NPD5789 | Clinical (unspecified phase) |
0.6552 | Remote Similarity | NPD9557 | Clinical (unspecified phase) |
0.6439 | Remote Similarity | NPD7914 | Suspended |
0.64 | Remote Similarity | NPD1454 | Phase 3 |
0.64 | Remote Similarity | NPD1455 | Phase 3 |
0.6393 | Remote Similarity | NPD1446 | Phase 3 |
0.6393 | Remote Similarity | NPD1447 | Phase 3 |
0.6357 | Remote Similarity | NPD1385 | Discontinued |
0.6299 | Remote Similarity | NPD7651 | Approved |
0.6281 | Remote Similarity | NPD9565 | Discontinued |
0.6279 | Remote Similarity | NPD6946 | Approved |
0.625 | Remote Similarity | NPD7139 | Approved |
0.625 | Remote Similarity | NPD7140 | Approved |
0.625 | Remote Similarity | NPD7141 | Clinical (unspecified phase) |
0.6207 | Remote Similarity | NPD9556 | Approved |
0.6198 | Remote Similarity | NPD755 | Phase 3 |
0.6154 | Remote Similarity | NPD9561 | Approved |
0.6154 | Remote Similarity | NPD9560 | Approved |
0.6142 | Remote Similarity | NPD2255 | Approved |
0.6133 | Remote Similarity | NPD7761 | Suspended |
0.6111 | Remote Similarity | NPD502 | Approved |
0.6102 | Remote Similarity | NPD9546 | Phase 2 |
0.6068 | Remote Similarity | NPD9558 | Phase 3 |
0.605 | Remote Similarity | NPD280 | Approved |
0.605 | Remote Similarity | NPD9533 | Phase 2 |
0.6033 | Remote Similarity | NPD1760 | Approved |
0.6014 | Remote Similarity | NPD6935 | Phase 3 |
0.6014 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.595 | Remote Similarity | NPD240 | Phase 3 |
0.595 | Remote Similarity | NPD9562 | Discovery |
0.595 | Remote Similarity | NPD170 | Approved |
0.5935 | Remote Similarity | NPD841 | Approved |
0.5878 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.5873 | Remote Similarity | NPD501 | Phase 1 |
0.584 | Remote Similarity | NPD6943 | Clinical (unspecified phase) |
0.5833 | Remote Similarity | NPD9529 | Phase 1 |
0.5833 | Remote Similarity | NPD9559 | Phase 1 |
0.5809 | Remote Similarity | NPD1805 | Phase 2 |
0.5809 | Remote Similarity | NPD1804 | Phase 2 |
0.5785 | Remote Similarity | NPD239 | Phase 2 |
0.5785 | Remote Similarity | NPD238 | Clinical (unspecified phase) |
0.5781 | Remote Similarity | NPD762 | Discontinued |
0.5772 | Remote Similarity | NPD9603 | Phase 3 |
0.5772 | Remote Similarity | NPD9602 | Phase 3 |
0.5772 | Remote Similarity | NPD9604 | Approved |
0.5746 | Remote Similarity | NPD1428 | Phase 2 |
0.5735 | Remote Similarity | NPD6941 | Approved |
0.5714 | Remote Similarity | NPD251 | Approved |
0.5714 | Remote Similarity | NPD2633 | Phase 1 |
0.5714 | Remote Similarity | NPD1407 | Approved |
0.5714 | Remote Similarity | NPD4743 | Phase 2 |
0.5692 | Remote Similarity | NPD881 | Approved |
0.568 | Remote Similarity | NPD618 | Clinical (unspecified phase) |
0.5674 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.5662 | Remote Similarity | NPD6693 | Phase 3 |
0.5634 | Remote Similarity | NPD6918 | Phase 1 |
PubChem CID   | 17473 |
ChEMBL   | CHEMBL228057 |
ZINC   |
Molecular Weight:   | 580.03 |
ALogP:   | -4.5643 |
MLogP:   | 0.69 |
XLogP:   | -5.62 |
# Rotatable Bonds:   | 18 |
Polar Surface Area:   | 331.72 |
# H-Bond Aceptor:   | 20 |
# H-Bond Donor:   | 9 |
# Rings:   | 3 |
# Heavy Atoms:   | 37 |